Tanno Luciana Kase, Demoly Pascal
Hospital Sírio-Libanês, São Paulo, Brazil.
University Hospital of Montpellier, Montpellier, France.
Pediatr Allergy Immunol. 2020 Nov;31 Suppl 26:8-10. doi: 10.1111/pai.13336.
Anaphylaxis in children is a potential acute life-threatening systemic hypersensitivity reaction. Anaphylaxis fatality rate is estimated to be 0.65% to 2%. Food is the main anaphylaxis trigger in children, notably cow's milk, peanuts, and tree nuts. Mucocutaneous manifestations are observed in more than 90% of cases, but it is not essential for diagnosis. Deaths are rather secondary to the laryngeal edema, observed in 40%-50% of cases. Personal history of asthma, allergy to particular foods such as peanuts and tree nuts, and adolescence are known risk factors for anaphylaxis and more severe reactions. Epinephrine (adrenaline) is the medication of choice for the first-aid treatment of anaphylaxis. However, adrenaline auto-injectors (AAIs) are commercially available in only 32% of world countries. There are still considerable unmet needs in the field of anaphylaxis in children. Therefore, the Montpellier WHO Collaborating Centre aims to start the global action plan applied to anaphylaxis.
儿童过敏反应是一种潜在的、危及生命的急性全身性超敏反应。据估计,过敏反应的死亡率为0.65%至2%。食物是儿童过敏反应的主要诱因,尤其是牛奶、花生和坚果。超过90%的病例会出现皮肤黏膜表现,但这并非诊断的必要条件。死亡多继发于喉水肿,40%-50%的病例会出现这种情况。哮喘个人史、对花生和坚果等特定食物过敏以及青春期是已知的过敏反应和更严重反应的危险因素。肾上腺素是过敏反应急救治疗的首选药物。然而,肾上腺素自动注射器在全球仅有32%的国家有商业销售。儿童过敏反应领域仍有相当大的未满足需求。因此,蒙彼利埃世界卫生组织合作中心旨在启动适用于过敏反应的全球行动计划。